Amlexanox

NMD inhibitor leading to full-lenght protein synthesis from nonsense mutation-containing RNA

Phase of research

FDA-approved for Other Purpose

How it helps

Restore CFTR Function

General information

Amlexanox is an anti-inflammatory antiallergic immunomodulator. It was approved in 1996 in the USA but has been discontinued. Amlexanox is still used in Japan to treat aphthous ulcers of the mouth, bronchial asthma, allergic rhinitis, and conjunctivitis. In relation to cystic fibrosis, our AIM tool found the data that amlexanox helps produce full-length protein from nonsense mutation-CFTR.

Amlexanox on PubChem
Amlexanox on DrugBank
Amlexanonx on Wikipedia

Synonyms

N/A

Marketed as

N/A

Dietary sources

N/A

C₁₆H₁₄N₂O₄

Drug-Mutation Relation

results for 2184delA / W1098X

See all data on Amlexanox

Treats

Mutation	Link	Tested on	Impact factor	Notes
nonsense mutations	Rescue of nonsense mutations by amlexanox in human cells	human cell cultures	4.32

Does not treat

Mutation	Link	Tested on	Impact factor	Notes